Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs

You may also be interested in...



Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

After A Record Year, China Healthcare IPOs Have Endured A Tough 2011

SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms

Related Content

Latest News
UsernamePublicRestriction

Register

SC073398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel